AU780061B2 - Transmembrane protein expressed in prostate and other cancers - Google Patents

Transmembrane protein expressed in prostate and other cancers Download PDF

Info

Publication number
AU780061B2
AU780061B2 AU42425/00A AU4242500A AU780061B2 AU 780061 B2 AU780061 B2 AU 780061B2 AU 42425/00 A AU42425/00 A AU 42425/00A AU 4242500 A AU4242500 A AU 4242500A AU 780061 B2 AU780061 B2 AU 780061B2
Authority
AU
Australia
Prior art keywords
leu
protein
cancer
gly
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU42425/00A
Other languages
English (en)
Other versions
AU4242500A (en
Inventor
Daniel E. Afar
Rene S. Hubert
Kahan Leong
Arthur B. Raitano
Douglas C. Saffran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of AU4242500A publication Critical patent/AU4242500A/en
Assigned to AGENSYS, INC. reassignment AGENSYS, INC. Amend patent request/document other than specification (104) Assignors: UROGENESYS, INC.
Application granted granted Critical
Publication of AU780061B2 publication Critical patent/AU780061B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU42425/00A 1999-04-12 2000-04-12 Transmembrane protein expressed in prostate and other cancers Expired AU780061B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12885899P 1999-04-12 1999-04-12
US60/128858 1999-04-12
PCT/US2000/010039 WO2000061746A1 (en) 1999-04-12 2000-04-12 13 transmembrane protein expressed in prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2005202143A Division AU2005202143B2 (en) 1999-04-12 2005-05-18 Transmembrane protein expressed in prostate and other cancers

Publications (2)

Publication Number Publication Date
AU4242500A AU4242500A (en) 2000-11-14
AU780061B2 true AU780061B2 (en) 2005-02-24

Family

ID=22437339

Family Applications (2)

Application Number Title Priority Date Filing Date
AU42425/00A Expired AU780061B2 (en) 1999-04-12 2000-04-12 Transmembrane protein expressed in prostate and other cancers
AU2005202143A Expired AU2005202143B2 (en) 1999-04-12 2005-05-18 Transmembrane protein expressed in prostate and other cancers

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2005202143A Expired AU2005202143B2 (en) 1999-04-12 2005-05-18 Transmembrane protein expressed in prostate and other cancers

Country Status (6)

Country Link
EP (2) EP2365081A3 (https=)
JP (4) JP2002541800A (https=)
AU (2) AU780061B2 (https=)
CA (1) CA2369413C (https=)
IL (3) IL145775A0 (https=)
WO (1) WO2000061746A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002352976B2 (en) * 2002-11-27 2007-11-08 Agensys, Inc. Nucleic acid corresponding protein entitled 24P4C12 useful in treatment and detection of cancer

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
US7244827B2 (en) 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
JP2004523236A (ja) * 2001-02-16 2004-08-05 インサイト・ゲノミックス・インコーポレイテッド 神経伝達関連タンパク質
PT2185574E (pt) * 2007-09-07 2013-08-26 Agensys Inc Anticorpos e moléculas relacionadas que se ligam a proteínas 24p4c12
US8309093B2 (en) 2009-03-06 2012-11-13 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 24P4C12 proteins
JP5122592B2 (ja) * 2010-01-04 2013-01-16 アジェンシス，インコーポレイテッド 癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
US11485972B2 (en) 2017-05-18 2022-11-01 Modernatx, Inc. Modified messenger RNA comprising functional RNA elements

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
DK0489149T3 (da) 1990-06-27 2001-12-27 Univ Princeton Prober til påvisning af mutant P53
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
DE69532127T2 (de) 1994-07-20 2004-08-26 Genetics Institute, Inc., Cambridge Interaktions-fullensysteme zum nachweis von protein-interaktionen
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
NZ306767A (en) 1995-04-11 2000-03-27 Univ Johns Hopkins Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
CA2252886C (en) 1996-04-26 2008-02-12 Massachusetts Institute Of Technology Three-hybrid screening assay
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
JP2001502537A (ja) 1996-10-15 2001-02-27 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア ヒト前立腺ガンの進行の動物モデル
US5846722A (en) 1996-10-16 1998-12-08 Terrapin Technologies, Inc. System to detect small molecule/peptide interaction
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
JP2001512013A (ja) * 1997-08-01 2001-08-21 ジェンセット 前立腺に発現される分泌タンパク質の５’ｅｓｔ
WO1999006548A2 (en) * 1997-08-01 1999-02-11 Genset 5'ESTs FOR NON TISSUE SPECIFIC SECRETED PROTEINS
AU8555098A (en) * 1997-08-01 1999-02-22 Genset 5' ests for secreted proteins expressed in testis and other tissues
CA2328895A1 (en) * 1998-06-02 1999-12-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROWEN ET AL EMBL ACC. NO. AF134726 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002352976B2 (en) * 2002-11-27 2007-11-08 Agensys, Inc. Nucleic acid corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
AU2008200628B2 (en) * 2002-11-27 2009-05-07 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer

Also Published As

Publication number Publication date
AU2005202143B2 (en) 2007-09-13
IL206604A0 (en) 2011-07-31
AU2005202143A1 (en) 2005-06-09
EP1171595A1 (en) 2002-01-16
WO2000061746A1 (en) 2000-10-19
AU4242500A (en) 2000-11-14
EP2365081A3 (en) 2012-07-18
IL206604A (en) 2013-07-31
IL145775A (en) 2010-11-30
JP2013136574A (ja) 2013-07-11
JP2010051321A (ja) 2010-03-11
JP2007314543A (ja) 2007-12-06
JP2002541800A (ja) 2002-12-10
CA2369413C (en) 2013-07-09
EP2365081A2 (en) 2011-09-14
CA2369413A1 (en) 2000-10-19
IL145775A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
US8383777B2 (en) 13-transmembrane protein expressed in prostate cancer
US6602501B1 (en) C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
JP2013136574A (ja) 前立腺癌において発現される１３回膜貫通タンパク質
AU2005201916B2 (en) G protein-coupled receptor up-regulated in prostate cancer and uses thereof
EP1250434B1 (en) 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
US20040265310A1 (en) Novel prostate-restricted gene expressed in prostate cancer
AU2007249104B2 (en) Transmembrane protein expressed in prostate and other cancers
AU2008202349B8 (en) 84P2A9: A prostate and testis specific protein highly expressed in prostate cancer
EP1792989A1 (en) 13 Transmembrane protein expressed in prostate cancer

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: AGENSYS, INC.

Free format text: FORMER NAME: UROGENESYS, INC.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND INVENTION TITLE TO READ: TRANSMEMBRANE PROTEIN EXPRESSED IN PROSTATE AND OTHER CANCERS

MK14 Patent ceased section 143(a) (annual fees not paid) or expired